Justin Zelin
Stock Analyst at BTIG
(1.45)
# 3,388
Out of 4,906 analysts
38
Total ratings
25.71%
Success rate
-1.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Buy | $64 → $20 | $3.21 | +523.05% | 2 | Jul 7, 2025 | |
| IBRX ImmunityBio | Initiates: Buy | $6 | $2.69 | +123.46% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $21.81 | +92.57% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.39 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $21.81 | +184.27% | 2 | Jul 9, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.84 | +552.17% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $8.20 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $31.97 | +291.05% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $5.08 | +432.02% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $2.06 | +38,829.44% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $36.90 | +146.61% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.74 | +1,257.40% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $3.22 | +397.67% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $10.12 | +265.61% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $9.74 | +259.34% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $42.20 | +113.27% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.46 | +379.88% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $64.92 | -76.12% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.53 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.22 | +719.67% | 3 | Nov 16, 2022 |
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $64 → $20
Current: $3.21
Upside: +523.05%
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $2.69
Upside: +123.46%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $21.81
Upside: +92.57%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $21.81
Upside: +184.27%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.84
Upside: +552.17%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.20
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $31.97
Upside: +291.05%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $5.08
Upside: +432.02%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $2.06
Upside: +38,829.44%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $36.90
Upside: +146.61%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.74
Upside: +1,257.40%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $3.22
Upside: +397.67%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $10.12
Upside: +265.61%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $9.74
Upside: +259.34%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $42.20
Upside: +113.27%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.46
Upside: +379.88%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $64.92
Upside: -76.12%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.53
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.22
Upside: +719.67%